Across TCGA pan-cancer cohorts, ECI2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ECI2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ECI2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ECI2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where ECI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.504	0.977	.005	25	view →
CCRCC	OS	Tertile	II,III,IV	1.000	0.713	.002	24	view →
HNSC	OS	Quartile	III,IV	0.866	0.557	.008	11	view →
PDAC	OS	Median	IV	0.395	0.937	.026	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ECI2 tumor-vs-normal RNA expression · all ECI2 data types